455 related articles for article (PubMed ID: 10458008)
1. Fecal excretion of alpha 2-macroglobulin: a novel marker for disease activity in patients with inflammatory bowel disease.
Becker K; Niederau C; Frieling T
Z Gastroenterol; 1999 Jul; 37(7):597-605. PubMed ID: 10458008
[TBL] [Abstract][Full Text] [Related]
2. Individual fecal alpha 1-antitrypsin excretion reflects clinical activity in Crohn's disease but not in ulcerative colitis.
Becker K; Berger M; Niederau C; Frieling T
Hepatogastroenterology; 1999; 46(28):2309-14. PubMed ID: 10521988
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
4. Quantification of fecal alpha 1-antitrypsin excretion for assessment of inflammatory bowel diseases.
Becker K; Frieling T; Häussinger D
Eur J Med Res; 1998 Feb; 3(1-2):65-70. PubMed ID: 9512970
[TBL] [Abstract][Full Text] [Related]
5. Fecal eosinophil granule-derived proteins reflect disease activity in inflammatory bowel disease.
Saitoh O; Kojima K; Sugi K; Matsuse R; Uchida K; Tabata K; Nakagawa K; Kayazawa M; Hirata I; Katsu K
Am J Gastroenterol; 1999 Dec; 94(12):3513-20. PubMed ID: 10606313
[TBL] [Abstract][Full Text] [Related]
6. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease.
Czub E; Herzig KH; Szaflarska-Popawska A; Kiehne K; Socha P; Woś H; Kamińska B; Błaszczyński M; Cichy W; Bała G; Brodzicki J; Grzybowska-Chlebowczyk U; Walkowiak J
Scand J Gastroenterol; 2007 Oct; 42(10):1147-50. PubMed ID: 17852864
[TBL] [Abstract][Full Text] [Related]
7. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins.
Sugi K; Saitoh O; Hirata I; Katsu K
Am J Gastroenterol; 1996 May; 91(5):927-34. PubMed ID: 8633583
[TBL] [Abstract][Full Text] [Related]
8. Enteric protein loss as a marker of intestinal inflammatory activity in Crohn's disease: comparability of enteric clearance and stool concentration of alpha-1-antitrypsin?
Hundegger K; Stufler M; Karbach U
Z Gastroenterol; 1992 Oct; 30(10):722-8. PubMed ID: 1441675
[TBL] [Abstract][Full Text] [Related]
9. IgG oligosaccharide alterations are a novel diagnostic marker for disease activity and the clinical course of inflammatory bowel disease.
Shinzaki S; Iijima H; Nakagawa T; Egawa S; Nakajima S; Ishii S; Irie T; Kakiuchi Y; Nishida T; Yasumaru M; Kanto T; Tsujii M; Tsuji S; Mizushima T; Yoshihara H; Kondo A; Miyoshi E; Hayashi N
Am J Gastroenterol; 2008 May; 103(5):1173-81. PubMed ID: 18177457
[TBL] [Abstract][Full Text] [Related]
10. The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity.
Clara I; Lix LM; Walker JR; Graff LA; Miller N; Rogala L; Rawsthorne P; Bernstein CN
Am J Gastroenterol; 2009 Jul; 104(7):1754-63. PubMed ID: 19455122
[TBL] [Abstract][Full Text] [Related]
11. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation.
Kane SV; Sandborn WJ; Rufo PA; Zholudev A; Boone J; Lyerly D; Camilleri M; Hanauer SB
Am J Gastroenterol; 2003 Jun; 98(6):1309-14. PubMed ID: 12818275
[TBL] [Abstract][Full Text] [Related]
12. [Initial personal experiences with alpha-1-antitrypsin determination in feces].
Schwery S; Meyenberger C; Ammann R; Wirth HP
Schweiz Med Wochenschr; 1995 Sep; 125(38):1783-7. PubMed ID: 7481635
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease.
Bansi DS; Chapman RW; Fleming KA
Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):881-5. PubMed ID: 8889455
[TBL] [Abstract][Full Text] [Related]
14. The forms and the levels of fecal PMN-elastase in patients with colorectal diseases.
Saitoh O; Sugi K; Matsuse R; Uchida K; Matsumoto H; Nakagawa K; Takada K; Yoshizumi M; Hirata I; Katsu K
Am J Gastroenterol; 1995 Mar; 90(3):388-93. PubMed ID: 7872275
[TBL] [Abstract][Full Text] [Related]
15. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease.
Winterkamp S; Weidenhiller M; Otte P; Stolper J; Schwab D; Hahn EG; Raithel M
Am J Gastroenterol; 2002 Dec; 97(12):3071-7. PubMed ID: 12492192
[TBL] [Abstract][Full Text] [Related]
16. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.
Sýkora J; Subrt I; Dìdek P; Siala K; Schwarz J; Machalová V; Varvarovská J; Pazdiora P; Pozler O; Stozický F
J Pediatr Gastroenterol Nutr; 2006 May; 42(5):479-87. PubMed ID: 16707968
[TBL] [Abstract][Full Text] [Related]
17. Relationship between fecal lactoferrin and inflammatory bowel disease.
Dai J; Liu WZ; Zhao YP; Hu YB; Ge ZZ
Scand J Gastroenterol; 2007 Dec; 42(12):1440-4. PubMed ID: 17852860
[TBL] [Abstract][Full Text] [Related]
18. Increased fecal eosinophil cationic protein in inflammatory bowel disease.
Berstad A; Børkje B; Riedel B; Elsayed S; Berstad A
Hepatogastroenterology; 1993 Jun; 40(3):276-8. PubMed ID: 8325594
[TBL] [Abstract][Full Text] [Related]
19. [Qualitative study of fecal alpha-1-antitrypsin in patients with inflammatory digestive disease and patients with ileostomy].
Colombel JF; Mizon C; Chekkouri N; Balduyck M; Chaussade S; Becuwe C; Degand P; Mizon J; Cortot A
Gastroenterol Clin Biol; 1991; 15(4):301-5. PubMed ID: 2060740
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease.
Peeters M; Joossens S; Vermeire S; Vlietinck R; Bossuyt X; Rutgeerts P
Am J Gastroenterol; 2001 Mar; 96(3):730-4. PubMed ID: 11280542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
